Investing in killing cancer STEM cells.

Dr. Weeks Comment: Again,  we see that as the focus is trained on the real dangerous cancer cell – the cancer STEM cell,  we will see solutions arise and the current standard of care (cut, burn  and poison – aka: surgery, radiation and chemotherapy)  will be abandoned and  Corrective Cancer Care will become the new standard.  The secret is anti-inflammation!

 

”…  Targeting the key biologic pathways thought to control cancer stem cells is also a key area for the company’s oncology research. Tarextumab, being developed in collaboration with OncoMed, is a first-in-class anti-cancer stem cell therapy in phase II development for the treatment of pancreatic and small cell lung cancer…”

 

Oncology

GSK has focussed its oncology discovery efforts to target the fundamental drivers of cancer, exploring new technologies and approaches to stimulate anti-tumour immunity, reprogram cancer cells and improve long-term survival. Development timelines for oncology drugs can be compressed, which offers potential for several of these assets to be filed with regulators in the next 3 to 5 years.

Epigenetics, the ‘control system’ that helps regulate the DNA of cells and determines cell function – including the initiation and progression of cancer – holds significant potential for future cancer therapies. GSK made a significant research commitment to the field of epigenetics in 2008 and has a number of strategic biotech and world-leading academic collaborations….

A first in class ICOS agonist antibody, GSK3359609, being developed in collaboration with INSERM, is focused on enhancing patients’ anti-tumour T-cell response and is expected to enter the clinic in Q1 2016, providing a potential universal mechanism across multiple cancers either alone or in combination treatments.

Targeting the key biologic pathways thought to control cancer stem cells is also a key area for the company’s oncology research. Tarextumab, being developed in collaboration with OncoMed, is a first-in-class anti-cancer stem cell therapy in phase II development for the treatment of pancreatic and small cell lung cancer.

Share This Post

Dr. Weeks Comment: Again,  we see that as the focus is trained on the real dangerous cancer cell – the cancer STEM cell,  we will see solutions arise and the current standard of care (cut, burn  and poison – aka: surgery, radiation and chemotherapy)  will be abandoned and  Corrective Cancer Care will become the new standard.…
&source=WeeksMD">